Therapies for Treatment-Resistant Depression: Neuropharmacology and Neurostimulation
Editat de James Murrough, Dennis Charneyen Limba Engleză Paperback – aug 2025
The last section consists of a set of chapters of special interest that includes current and future research directions, development of psilocybin-based interventions and other psychedelic compounds currently under study for TRD and advances in biomarker-guided and personalized treatment. Edited by world renowned experts in the field, this book is the ultimate resource for researchers and clinicians.
- Defines treatment-resistant depression, including epidemiology
- Outlines neuroimaging and brain-based biomarkers in treatment-resistant depression using patient data
- Reviews safety and monitoring protocols of ketamine in clinical care
Preț: 903.78 lei
Preț vechi: 993.16 lei
-9% Nou
Puncte Express: 1356
Preț estimativ în valută:
172.96€ • 180.34$ • 143.74£
172.96€ • 180.34$ • 143.74£
Carte nepublicată încă
Doresc să fiu notificat când acest titlu va fi disponibil:
Se trimite...
Preluare comenzi: 021 569.72.76
Specificații
ISBN-13: 9780443160059
ISBN-10: 0443160058
Pagini: 425
Dimensiuni: 191 x 235 mm
Editura: ELSEVIER SCIENCE
ISBN-10: 0443160058
Pagini: 425
Dimensiuni: 191 x 235 mm
Editura: ELSEVIER SCIENCE
Cuprins
1. Introduction
2. Treatment-Resistant Depression: Epidemiology and Clinical Presentation
3. Molecular Neuropharmacology of Treatment-Resistant Depression
4. Neurobiology and Neuroimaging of Treatment-Resistant Depression
5. Pharmacotherapy of Treatment-Resistant Depression: Overview and Look Ahead
6. Lithium, Dopamine Modulators, and Other Augmentation Strategies for Treatment-Resistant Depression
7. Ketamine and Esketamine for Treatment-Resistant Depression
8. The Impact of Inflammation on Treatment Resistance in Depression: Mechanisms and Translational Opportunities
9. Novel Pharmacotherapies for Treatment-Resistant Depression: A Focus on Glutamate and GABA Modulators
10. Electroconvulsive Therapy for Treatment-Resistant Depression
11. Transcranial Magnetic Stimulation for Treatment-Resistant Depression
12. Vagal Nerve Stimulation for Treatment-Resistant Depression
13. Deep Brain Stimulation for Treatment-Resistant Depression
14. Psilocybin and Other Psychedelic Agents in Development for Treatment-Resistant Depression
15. Neuroimaging Biomarkers in Treatment Selection for Treatment-Resistant Depression
16. The Role of Genetics in Treatment-Resistant Depression
2. Treatment-Resistant Depression: Epidemiology and Clinical Presentation
3. Molecular Neuropharmacology of Treatment-Resistant Depression
4. Neurobiology and Neuroimaging of Treatment-Resistant Depression
5. Pharmacotherapy of Treatment-Resistant Depression: Overview and Look Ahead
6. Lithium, Dopamine Modulators, and Other Augmentation Strategies for Treatment-Resistant Depression
7. Ketamine and Esketamine for Treatment-Resistant Depression
8. The Impact of Inflammation on Treatment Resistance in Depression: Mechanisms and Translational Opportunities
9. Novel Pharmacotherapies for Treatment-Resistant Depression: A Focus on Glutamate and GABA Modulators
10. Electroconvulsive Therapy for Treatment-Resistant Depression
11. Transcranial Magnetic Stimulation for Treatment-Resistant Depression
12. Vagal Nerve Stimulation for Treatment-Resistant Depression
13. Deep Brain Stimulation for Treatment-Resistant Depression
14. Psilocybin and Other Psychedelic Agents in Development for Treatment-Resistant Depression
15. Neuroimaging Biomarkers in Treatment Selection for Treatment-Resistant Depression
16. The Role of Genetics in Treatment-Resistant Depression